Conference Program*

All times listed are Sedona, AZ Mountain Time (MT)


View this event in your time zone

Thursday, November 4

Registration Open
5:30-7 p.m.

Welcome Reception
7:30-9:30 p.m.

Friday, November 5

Registration
8 a.m.-5 p.m.

Breakfast
7:30-8:30 a.m.

Scientific Session 1: Novel Payloads and Mechanisms of Action 1
Chairpersons: John Bell, PhD, and Grant McFadden, PhD
8:30-10:08 a.m.

  • David Stojdl, PhD
    8:30-8:55 a.m.

  • Leslie Sharp, PhD, OncoMyx Therapeutics
    Multi-armed myxoma virus demsonstrates activity in preclinical models
    8:55-9:20 a.m.

  • Oral Abstract 1
    Shaun Zhang, MD, University of Houston
    Co-delivery of Novel bi-Specific and tri-Specific Engagers by an Amplicon Vector Augments the Therapeutic Effect of a HSV-based Oncolytic Virotherapy
    9:20-9:32 a.m.

  • Oral Abstract 2
    Nikolas Martin, PhD, Ottawa Hospital Research Institute
    An oncolytic vaccinia virus encoding virus-like-particles and self-amplifying RNA replicons: Teaching new tricks to an old virus 

    9:32-9:44 a.m.

  • Oral Abstract 3
    Bart Spiesschae, DVM, PhD, ViraTherapeutics GmbH
    Lymphotoxin-α-armed oncolytic VSV-GP synergizes with SMAC mimetics to induce enhanced tumor cell death and regression
    9:44-9:56 a.m.

  • Oral Abstract 4, 
    John Christie, MS, Arizona State University School of Life Sciences
    Delivery and Efficacy of LIGHT-armed Myxoma Virus in a Syngeneic Lung Metastatic Murine Osteosarcoma
    9:56-10:08 a.m.

Coffee Break
10:08-10:30 a.m.

Scientific Session 2: Novel Payloads and Mechanisms of Action 2
Chairpersons: John Bell, PhD, and Grant McFadden, PhD
10:35 a.m.-11:56 a.m.

  • Leonard Seymour, PhD, University of Oxford
    Arming oncolytic DNA viruses to improve their anticancer impact
    10:30-10:55 a.m.

  • Balveen Kaur, PhD, McGovern Medical School
    Oncolytic Viral therapy signaling NOTCH
    10:55-11:20 a.m.

  • Oral Abstract 5
    Haifei Jiang, PhD, Mayo Clinic
    Herpesviral Combination Therapy For Targeting Both Cancer Cells And Cancer Associated Stromal Cells
    11:20-11:32 a.m.

  • Oral Abstract 6
    Flurin Caviezel, MSc, University of Oxford
    Targeting the Extracellular Matrix to Overcome Immunosuppression Using Bi-Specifics Delivered by Oncolytic Viruses
    11:32-11:44 a.m.

  • Oral Abstract 7
    Emanuele Sasso, PhD, University of Naples Federico
    Arming Oncolytic Herpes Virus with Adenosine Deaminase Enzyme for Clearance of Immunosuppressive Tumor Adenosine
    11:44-11:56 a.m.

Lunch
11:56 a.m.-12:55 p.m.

Scientific Session 3: Novel Combinations and Mechanisms of Action
Chairpersons: Martine Lamfers, PhD, and Samuel Rabkin, PhD
12:55-2:33 p.m.

  • Kevin Harrington, PhD, The Institute of Cancer Research, London
    Mechanistic studies of drug-virus combinations reveal unexpected immunotherapeutic potential
    12:55-1:20 p.m.

  • Chae-Ok Yun, PhD, GeneMedicine Co., Ltd.
    Tumor-targeted systemic delivery of oncolytic adenoviruses using nanocarrier platform
    1:20-1:45 p.m.

  • Oral Abstract 8
    Lorella Tripodi, European School of Molecular Medicine (SEMM)
    Gut microbiome affects oncolytic adenovirus-mediated immunogenic cell death in a melanoma mouse model  

    1:45-1:57 p.m.

  • Oral Abstract 9
    Miriam Valenzuela, MSc, UNMHSC
    Tumor Necrosis Factor α plays multiple negative roles during oncolytic therapy both inhibiting systemic efficacy and exacerbating immune mediated toxicities   
    1:57-2:09 p.m.

  • Oral Abstract 10
    Guido Wollmann, MD, Medical University Innsbruck
    A Modular Self-Adjuvanting Cancer Vaccine Combined With An Oncolytic Vaccine Induces Potent Antitumor Immunity  
    2:09-2:21 p.m.

  • Oral Abstract 11
    Zaid Taha, MSc, Ottawa Hospital Research Institute, University of Ottawa
    Evaluation of Viral Sensitizing Antibody-Drug Conjugate (ADC) and Oncolytic Virus Combination Regimen in Novel Murine Models of HER2+ Cancer  
    2:21-2:33 p.m.

Coffee Break
2:33-2:45 p.m.

Scientific Session 4: Novel Combinations and Mechanisms of Action 2
2:45-4:11 p.m.

  • Alan Melcher, PhD, The Institute of Cancer Research, London
    Oncolytic Herpes Virus and BRAF Inhibitor Therapy for Melanoma: The Role and Application of CD4 T Cell Signaling Dynamics
    2:45-3:10 p.m.

  • Richard Vile, PhD
    3:10-3:35 p.m.

  • Oral Abstract 12
    Jahanara Rajwani, University of Calgary
    Oncolytic Virus Infection of Non Cancer Cells Improves Antitumour Immunity by Increasing Tumour-Antigen Specific T Cell Generation in the Lymph Node  
    3:35-3:47 p.m.

  • Oral Abstract 13
    Matthew Mullarkey, MD, McGovern Medical School, UTHSC
    Oncolytic HSV-P10 and Targeting of Glycolysis and Oxidative Phosphorylation as a Potential Therapy in the Treatment of Glioblastoma    
    3:47-3:59 p.m.

  • Oral Abstract 14
    Molly Holbrook, University of North Carolina at Charlotte
    Screening of FDA-Approved Drug Library for Combinatorial Treatment of Pancreatic Cancer Cells with Oncolytic Vesicular Stomatitis Virus
    3:59-4:11 p.m.

Scientific Session 5: Clinical Trials 1
Chairpersons: E. Antonio Chiocca, M.D., Ph.D., FAANS, and Chae-Ok Yun, PhD
4:11-5:26 p.m.

  • E. Antonio Chiocca, MD, PhD, FAANS, Harvard Medical School
    First In Human Clinical Trials of New Oncolytic Virus Expressing ICP34.5 for Glioblastoma
    4:11-4:36 p.m.

  • Joselle Cook, MD, Mayo Clinic
    Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Hematologic Malignancies
    4:36-5:01 p.m.

  • Tomoki Todo, PhD, University of Tokyo
    Clinical development and approval of oncolytic herpes virus G47∆
    5:01-5:26 p.m.

Dinner (Off-site Cook Out)
6-9 p.m.

Satuday, November 6

Registration
8 a.m.-5 p.m.

Breakfast
7:30-8:30 a.m.

Scientific Session 6: Novel Viral Platforms 1
Chairperson: Noriyuki Kasahara, MD, PhD
8:30-9:56 a.m.

  • Stephen Russell, MD, PhD
    8:30-8:55 a.m.

  • Oral Abstract 15
    Sara Feola, University of Helsinki
    A Novel Immunopeptidomic-Based Pipeline for the Generation of Personalized Oncolytic Cancer Vaccines  
    8:55-9:07 a.m.

  • Oral Abstract 16
    Karol Budzik, PhD, Mayo Clinic
    Development and Characterization of a Foamy Virus-Based Oncolytic Replicating Retroviral Vector
    9:07-9:19 a.m.

  • Oral Abstract 17
    Liang Deng, MD, PhD, Memorial Sloan Kettering Cancer Center
    TARGETING REGULATORY T CELLS AND EXHAUSTED T CELLS BY A SECOND-GENERATION RECOMBINANT MODIFIED VACCINAI VIRUS ANKARA  
    9:19-9:31 a.m.

  • Yuman Fong, MD, City of Hope Medical Center
    Redesigning the Pox Virus for Oncolytic Therapy
    9:31-9:56 a.m.

Coffee Break
9:56-10:15 a.m.

Scientific Session 7: Novel Platforms 2
Chairperson: Stephen J. Russell, MD, PhD
10:15 a.m.-11:16 a.m.

  • Autumn Schulze, PhD, Mayo Clinic
    Synthetic Infectious RNA-Based Oncolytic Immunotherapy
    10:15-10:40 a.m.

  • Oral Abstract 18
    Xinping Fu, MD, University of Houston
    Novel Strategies to Modify an Oncolytic HSV for Systemic Delivery  
    10:40-10:52 a.m.

  • Oral Abstract 19
    Alexander Haddad, MD, UCSF
    A Synthetic Novel Replicating Retroviral Gene Therapy Platform for the Treatment of Glioblastoma
    10:52-11:04 a.m.

  • Oral Abstract 20
    Velia Penza, MS, Mayo Clinic
    Deletion of the polycytidine (polyC) tract in oncolytic miRNA-detargeted Mengovirus increases its therapeutic efficacy in a murine multiple myeloma model
    11:04-11:16 a.m.

Lunch
11:16 a.m.-11:40 a.m.

Keynote Speaker Session
11:40 a.m.-1:05 p.m.

  • Announcement of Abstract Travel Award Winners
    11:40 a.m.-12 p.m.

  • Introduction to Keynote Speaker
    12-12:05 p.m.

  • Larry Corey, MD, Fred Hutchinson Cancer Research Center
    The Trek Toward COVID-19 Vaccines: How We Got There and What's Left to Accomplish
    12:05-1:05 p.m.     

Afternoon Activities
1:05-6 p.m.

Special Session
Chairperson: Kah Whye Peng, PhD, and David Stojdl, PhD
7-9 p.m.

Sunday, November 7

Registration
8 a.m.-5 p.m.

Breakfast
7:30-8:30 a.m.

Scientific Session 8: Clinical Trials 2
8:30-9:56 a.m.

  • Rob Coffin, PhD, Replimune Inc.
    Next Generation Oncolytic HSV
    8:30-8:55 a.m.

  • Helen Gogas, MD, PhD, National and Kapodistrian University of Athens
    Amgen Phase 3 T-Vec Melanoma Trial
    8:55-9:20 a.m.

  • Oral Abstract 21
    Praveen Bommaredy, PhD, Replimune Inc.
    Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation 
    9:20-9:32 a.m.

  • Oral Abstract 22
    Shruthi Naik, PhD, Mayo Clinic
    SAFETY AND EFFICACY OF NEOADJUVANT INTRAVESICAL ONCOLYTIC MV-NIS IN PATIENTS WITH UROTHELIAL CARCINOMA

    9:32-9:44 a.m.

  • Oral Abstract 23
    Guy Ungerechts, MD, PhD, National Center for Tumor Diseases Heidelberg
    Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Immune Cell Activity in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    9:44-9:56 a.m.

Coffee Break
10-10:30 a.m.

Scientific Session 9: Clinical Trials 3
10:30 a.m.-12:08 p.m.

  • Maciej S. Lesniak, MD, Northwestern Feinberg School of Medicine
    Neural Stem Cell Delivery of Oncolytic Virotherapy for Glioma
    10:30-10:55 a.m.

  • Evanthia Galanis, MD, Mayo Clinic
    First in human Testing of Measles Virus Infected Mesenchymal Stem Cells
    10:55-11:20 a.m.

  • Oral Abstract 24
    Adel Samson, PhD, University of Leeds
    Neoadjuvant Oncolytic Pexa Vec for Patients with Colorectal Cancer Liver Metastases  
    11:20-11:32 a.m.

  • Oral Abstract 25
    Parker Dryja, UNMHSC
    Altered Arginine Metabolism within the Tumor Microenvironment Inhibits Oncolytic Myxoma Virus Replication Preventing Effective Therapy  
    11:32-11:44 a.m.

  • Oral Abstract 26
    Miriam Bazan-Peregrino, DPhil, VCN Biosciences
    Oncolytic Adenovirus VCN-01 Targeting the Dysfunctional Rb Pathway Is an Encouraging Therapy Against Retinoblastoma

    11:44-11:56 a.m.

  • Oral Abstract 27
    James Burke, MD, Moffit Cancer Center
    CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)  

    11:56 a.m.-12:08 p.m.

Lunch
12:08-1:08 p.m.

Virtual Poster Presentations
1-3:30 p.m.

Coffee Break
3:30-4 p.m.

The Great Debate
Moderator: Stephen J. Russell, MD, PhD
Complex large viruses are superior to small, elegant viruses
4-5:30 p.m.

Farewell Dinner
6:30-9:30 p.m.

*Program subject to change.

2022

ASGCT 25th Annual Meeting

May 16-19, 2022

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.